194 related articles for article (PubMed ID: 28262196)
1. Serum Chemerin in Obese Children and Adolescents Before and After L-Carnitine Therapy: Relation to Nonalcoholic Fatty Liver Disease and Other Features of Metabolic Syndrome.
Hamza RT; Elkabbany ZA; Shedid AM; Hamed AI; Ebrahim AO
Arch Med Res; 2016 Oct; 47(7):541-549. PubMed ID: 28262196
[TBL] [Abstract][Full Text] [Related]
2. Chemerin, retinol binding protein-4, cytokeratin-18 and transgelin-2 presence in sera of patients with non-alcoholic liver fatty disease.
Zwolak A; Szuster-Ciesielska A; Daniluk J; Semeniuk J; Kandefer-Szerszen M
Ann Hepatol; 2016 Nov-Dec 2016; 15(6):862-869. PubMed ID: 27740519
[TBL] [Abstract][Full Text] [Related]
3. Chemerin as a novel non-invasive serum marker of intrahepatic lipid content in obese children.
Kłusek-Oksiuta M; Bialokoz-Kalinowska I; Tarasów E; Wojtkowska M; Werpachowska I; Lebensztejn DM
Ital J Pediatr; 2014 Nov; 40():84. PubMed ID: 25399407
[TBL] [Abstract][Full Text] [Related]
4. Serum Pentraxin 3 Fragment as a Noninvasive Marker of Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents.
Hamza RT; Elfaramawy AA; Mahmoud NH
Horm Res Paediatr; 2016; 86(1):11-20. PubMed ID: 27309736
[TBL] [Abstract][Full Text] [Related]
5. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
6. Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress.
Farhangi MA; Alipour B; Jafarvand E; Khoshbaten M
Arch Med Res; 2014 Oct; 45(7):589-95. PubMed ID: 25450583
[TBL] [Abstract][Full Text] [Related]
7. Decrease in serum chemerin through aerobic exercise plus dieting and its association with mitigation of cardio-metabolic risk in obese female adolescents.
Liu M; Lin X; Wang X
J Pediatr Endocrinol Metab; 2018 Jan; 31(2):127-135. PubMed ID: 29306931
[TBL] [Abstract][Full Text] [Related]
8. Serum Chemerin Concentrations Associate with Beta-Cell Function, but Not with Insulin Resistance in Individuals with Non-Alcoholic Fatty Liver Disease (NAFLD).
Hatziagelaki E; Herder C; Tsiavou A; Teichert T; Chounta A; Nowotny P; Pacini G; Dimitriadis G; Roden M
PLoS One; 2015; 10(5):e0124935. PubMed ID: 25933030
[TBL] [Abstract][Full Text] [Related]
9. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
[TBL] [Abstract][Full Text] [Related]
10. Link between chemerin, central obesity, and parameters of the Metabolic Syndrome: findings from a longitudinal study in obese children participating in a lifestyle intervention.
Niklowitz P; Rothermel J; Lass N; Barth A; Reinehr T
Int J Obes (Lond); 2018 Oct; 42(10):1743-1752. PubMed ID: 30030480
[TBL] [Abstract][Full Text] [Related]
11. Serum Osteocalcin Levels in Children With Nonalcoholic Fatty Liver Disease.
Amin S; El Amrousy D; Elrifaey S; Gamal R; Hodeib H
J Pediatr Gastroenterol Nutr; 2018 Jan; 66(1):117-121. PubMed ID: 28991837
[TBL] [Abstract][Full Text] [Related]
12. Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis.
Pohl R; Haberl EM; Rein-Fischboeck L; Zimny S; Neumann M; Aslanidis C; Schacherer D; Krautbauer S; Eisinger K; Weiss TS; Buechler C
Eur J Clin Invest; 2017 Jan; 47(1):7-18. PubMed ID: 27797398
[TBL] [Abstract][Full Text] [Related]
13. Are serum chemerin levels different between obese and non-obese polycystic ovary syndrome women?
Yang S; Wang Q; Huang W; Song Y; Feng G; Zhou L; Tan J
Gynecol Endocrinol; 2016; 32(1):38-41. PubMed ID: 26291816
[TBL] [Abstract][Full Text] [Related]
14. Serum chemerin in children with excess body weight may be associated with ongoing metabolic complications - A pilot study.
Sledzińska M; Szlagatys-Sidorkiewicz A; Brzezinski M; Kaźmierska K; Sledziński T; Kamińska B
Adv Med Sci; 2017 Sep; 62(2):383-386. PubMed ID: 28551507
[TBL] [Abstract][Full Text] [Related]
15. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
[TBL] [Abstract][Full Text] [Related]
16. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity.
Bekaert M; Ouwens DM; Hörbelt T; Van de Velde F; Fahlbusch P; Herzfeld de Wiza D; Van Nieuwenhove Y; Calders P; Praet M; Hoorens A; Geerts A; Verhelst X; Kaufman JM; Lapauw B
Obesity (Silver Spring); 2016 Dec; 24(12):2544-2552. PubMed ID: 27768254
[TBL] [Abstract][Full Text] [Related]
17. Serum chemerin and vaspin in non-alcoholic fatty liver disease.
Kukla M; Zwirska-Korczala K; Hartleb M; Waluga M; Chwist A; Kajor M; Ciupinska-Kajor M; Berdowska A; Wozniak-Grygiel E; Buldak R
Scand J Gastroenterol; 2010; 45(2):235-42. PubMed ID: 20095887
[TBL] [Abstract][Full Text] [Related]
18. The comparison of chemerin, adiponectin and lipid profile indices in obese and non-obese adolescents.
Maghsoudi Z; Kelishadi R; Hosseinzadeh-Attar MJ
Diabetes Metab Syndr; 2016; 10(2 Suppl 1):S43-6. PubMed ID: 27150200
[TBL] [Abstract][Full Text] [Related]
19. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease.
Sayın O; Tokgöz Y; Arslan N
J Pediatr Endocrinol Metab; 2014 May; 27(5-6):479-84. PubMed ID: 24468600
[TBL] [Abstract][Full Text] [Related]
20. Predictive Value of Adiposity Level, Metabolic Syndrome, and Insulin Resistance for the Risk of Nonalcoholic Fatty Liver Disease Diagnosis in Obese Children.
Prokopowicz Z; Malecka-Tendera E; Matusik P
Can J Gastroenterol Hepatol; 2018; 2018():9465784. PubMed ID: 29854716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
